Cipla’s US arm gets complete response letter from USFDA for IV Tramadol

13 Oct 2020 Evaluate

Cipla’s step-down US-based subsidiary -- Avenue Therapeutics, Inc has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (USFDA) regarding the Company’s New Drug Application (NDA) for IV tramadol.

The CRL stated that although the pivotal Phase 3 clinical trials demonstrated statistically significant outcomes for all of the primary and many secondary endpoints, the FDA has determined that it cannot approve the application in its present form. The CRL stated that IV tramadol, intended to treat patients in acute pain who require an opioid, is not safe for the intended patient population. Specifically, if a patient requires an analgesic between the first dose of IV tramadol and the onset of analgesia, a rescue analgesic would be needed. The likely choice would be another opioid, which would result in opioid stacking and increase the likelihood of opioid-related adverse effects. Other than this potential safety concern, the FDA did not identify a safety signal in Avenue’s clinical development program. In addition, the CRL stated that the FDA requires an adequate terminal sterilization validation prior to NDA approval, which is planned for later this quarter.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.

Cipla Share Price

1352.95 -23.10 (-1.68%)
18-Apr-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1523.80
Dr. Reddys Lab 5959.10
Cipla 1352.95
Zydus Lifesciences 934.50
Lupin 1599.65
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.